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Abstract 
Retinoblastoma (RB) is a children’s ocular cancer caused by mutated retinoblastoma 1 (Rb1) gene 
on both alleles. Rb1 and other related genes could be regulated by microRNAs (miRNA) via 
complementarily pairing with their target sites. MicroRNA-21 (miR-21) possesses the oncogenic 
potential to target several tumor suppressor genes, including PDCD4, and regulates tumor pro-
gression and metastasis. However, the mechanism of how miR-21 regulates PDCD4 is poorly 
understood in RB. We investigated the expression of miRNAs in RB cell lines and identified that 
miR-21 is one of the most deregulated miRNAs in RB. Using qRT-PCR, we verified the expression 
level of several miRNAs identified by independent microarray assays, and analyzed miRNA ex-
pression patterns in three RB cell lines, including Weri-Rb1, Y79 and RB355. We found that 
miR-19b, -21, -26a, -195 and -222 were highly expressed in all three cell lines, suggesting their 
potential role in RB tumorigenesis. Using the TargetScan program, we identified a list of potential 
target genes of these miRNAs, of which PDCD4 is one the targets of miR-21. In this study, we 
focused on the regulatory mechanism of miR-21 on PDCD4 in RB. We demonstrated an inverse 
correlation between miR-21 and PDCD4 expression in Weri-Rb1 and Y79 cells. These data 
suggest that miR-21 down-regulates Rb1 by targeting PDCD4 tumor suppressor. Therefore, 
miR-21 could serve as a therapeutic target for retinoblastoma. 
Key words: Retinoblastoma; miRNA; miR-21; PDCD4. 
Introduction 
Retinoblastoma (RB) is a common pediatric in-
traocular tumor represented by a mutation of the ret-
inoblastoma gene (Rb1) on both alleles. There are 
about 250-350 newly diagnosed RB cases every year in 
the United States [1, 2]. Retinal tumors develop rap-
idly in early childhood, usually before the age of five. 
Common treatments now include chemotherapy, fo-
cal therapy such as laser or cryotherapy, and enuclea-
tion [3]. Metastasis of RB is often fatal, despite the 
high cure rate in children [4]. Later in life, survivors 
with bilateral RB, an inheritable form, will face in-








cancers [5, 6], and a trilateral RB, known as 
pineoblastoma, a tumor in pineal gland [7]. Previous 
report indicates that 30-40% of all RBs were found to 
be bilateral [8, 9]. The metastasis could be seen in both 
heritable and inheritable cases, as tumor cells fre-
quently invade the optic nerve, orbit and choroid [10, 
11]. Thus, methods to minimize the requirement of 
enucleation, decrease the risk of tumor metastasis and 
the development of secondary cancers, preserve vi-
sion and prevent systemic toxicity are crucially 
needed [1]. 
The critical role of Rb1 in cell proliferation at-
tracted much attention after it was first discovered in 
RB. The Rb1 gene is located at chromosome 13q14 and 
functions as a tumor suppressor, which regulates the 
cell cycle, specifically cell proliferation and apoptosis. 
The retinoblastoma protein (pRb) binds to the tran-
scription factor of the E2F family to mediate the suc-
cession of the G1/S phase [12]. As described in 
Knudson’s “two-hit theory” model of tumorigenesis 
[13], the heritable form of RB is derived from one 
germ line mutation and one somatic mutation. On the 
other hand, the non-heritable or sporadic form is due 
to two somatic mutations. Loss of the Rb1 gene in RB 
is necessary for tumorigenic initiation as well as sub-
sequent genetic and epigenetic alterations causing 
tumor metastasis [1, 12, 14, 15]. 
miRNA is a small non-coding single-stranded 
RNA (18-24nt), widespread throughout the human 
genome. It is well documented for their 
post-transcriptional modifications on gene expression 
[16-18]. According to miRBase Release 21 (June 2014), 
2,588 mature human miRNAs have been identified 
[19, 20]. Primary miRNA (pri-miRNA) is transcribed 
by RNA polymerase II and then cleaved by endonu-
clease RNase III Drosha in the nucleus to release 
stem-loop shaped pre-miRNA, which are approxi-
mately 70 nucleotides in length [14, 21]. After being 
exported into the cytoplasm and processed by another 
endonuclease, Dicer, pre-miRNA becomes mature 
double-strand miRNA. One strand of mature miRNA 
is integrated into the RNA-induced silencing complex 
(RISC) to regulate target genes [16, 22]. Imperfectly or 
perfectly base pairing the 3’ UTR of a target mRNA 
with the conserved seed region (~5 nucleotides) in the 
5’ end of a miRNA caused genomic instability and 
transcriptional degradation, as well as translational 
repression [18, 21, 23, 24]. Furthermore, due to im-
portant features of miRNAs, a single miRNA can 
target more than one mRNA molecule and single 
target mRNA can be recognized by multiple miRNAs. 
The interaction between miRNAs and its targets cre-
ates a complex regulatory network [18, 22, 25].  
miRNA transcripts are often located at fragile 
genomic sites related to cancer and are expressed 
abnormally because of alterations in cancer genome 
[26, 27]. Several cancer-related miRNAs and their 
target genes in tumor cells have been identified [14, 
25] and their disposition clarified as either towards 
tumor suppression or oncogenesis [16, 18]. For in-
stance, loss of miRNA-15/-16 in chronic lymphocytic 
leukemia [16, 18, 27, 28], miRNA let-7 in lung cancer 
[16, 18, 27, 29], and miRNA-143/ miRNA-145 in colon 
cancer [30], miR-638 in breast cancer [31] provided 
some evidences towards the tumor suppressing ca-
pabilities of miRNA. Similarly, over-expressed 
miRNA-21/ miRNA-155 in human breast cancer [16, 
18, 32] showed the oncogenic potential of miRNAs. 
Recently, we found that a number of miRNAs, in-
cluding miR-21, are involved in early breast cancer 
progression using microarray assay on microdissect-
ed formalin-fixed paraffin-embedded (FFPE) samples 
[33].  
Targeting miRNAs could be a novel therapeutic 
option due to its regulatory role during cancer de-
velopment and progression. miRNA-34a was report-
ed as a tumor suppressor in RB cell lines [14]. The 
inverse correlation between down-regulated 
hsa-let-7b and overexpressed HMGA-1 and HMGA-2 
was found in FFPE RB tumor samples [15]. By profil-
ing miRNA expression in RB cell line HXO-RB44 un-
der normal and hypoxic conditions, researchers iden-
tified miR-181 as a hypoxia-related miRNA and that 
the inhibition of miR-181b impeded cell growth in RB 
cells under hypoxia conditions [34].  
In this study, we first tried to determine the ex-
pression of a set of miRNAs related to RB in three RB 
cell lines, Weri-Rb1, Y79 and RB 355. We found a list 
of five miRNAs: miR-19b, miR-21, miR-26a, miR-195 
and miR-222, which might be involved in the prolif-
eration and metastasis in RB. Then we analyzed the 
predicted target genes of these miRNA in RB pathol-
ogies by miRNA and mRNA interactions. Among 
them, miR-21 is well studied and is a known on-
co-miR that is highly expressed in cancers, such as 
breast cancer [35-37], glioblastoma [38, 39], glioma 
[40], colorectal cancer [41], prostate cancer [42, 43], 
hepatocellular cancer [44], non-small cell lung cancer 
[45], papillary thyroid carcinoma [46], gastric cancer 
[47], osteosarcoma [48], diffuse large B-cell lymphoma 
[49] and laryngeal carcinoma [50]. However, to the 
best of our knowledge, there is no report on the role of 
miR-21 in RB initiation and development. In this 
study, we focused on elucidating the role of miR-21 in 
regulating one of its target genes, the programmed 
cell death 4 (PDCD4), a tumor suppressor involving 
cell cycle regulation.  
 




Materials and Methods 
Cell culture 
The human RB cell lines Y79, Weri-RB1 and 
RB355 were provided by Dr. Hakim Djaballah at the 
Memorial Sloan-Kettering Cancer Center. They were 
cultured in RPMI-1640 (Lonza) with 1% penicil-
lin-streptomycin, 2 mM glutamine and 20% fetal bo-
vine serum (HyClone, Thermo Scientific) [51]. All cell 
lines were grown in suspension at a concentration of 
105 – 106 cells/ml and incubated at 37 ˚C with 5% CO2. 
Isolation of total RNAs and miRNAs 
Total RNAs and miRNAs from the cell lines 
were isolated using TRIzol® Reagent (Invitrogen) and 
the mirVana miRNA Isolation Kit (Ambion) respec-
tively. Concentration and purity of the RNA samples 
were assayed using the NanoDrop ND-1000 Spec-
trophotometer (NanoDrop, Wilmington, DE). 
qRT-PCR for miRNAs and mRNAs 
The Taqman MiRNA Reverse Transcript Kit 
(Applied Biosystems), wherein a stem-loop RT primer 
specifically hybridizes with a miRNA molecule and a 
MultiScribe™ Reverse Transcriptase, was used for 
reverse transcription (RT). The RT reaction mixture 
was incubated at 16˚C for 30 minutes, 42˚C for 30 
minutes, 85˚C for 5 minutes, and then stored at 4˚C. 
The RT products were subsequently amplified with 
the mature miRNA-specific Taqman® MiRNA Assay 
Kit (Applied Biosystems) using the ABI 7300 Re-
al-Time PCR system. The PCR was performed at 95 ˚C 
for 10 minutes, followed by 40 cycles of 95 ˚C for 15 
seconds and 60 ˚C for 60 seconds. U6 small nuclear 
RNA was used as an internal control for normaliza-
tion. PDCD4 primers were synthesized by the Inte-
grated DNA Technologies (IDT) and the sequences 
were as follows: Forward, 5’-GGC CTC CAA GGA 
GTA AGA CC-3’; Reverse, 5’-AGG GGT CTA CAT 
GGC AAC TG-3’. The cDNAs were synthesized via 
iScript cDNA Synthesis Kit (Bio-Rad Laboratories) 
and amplified with SYBR® GreenER™ qPCR Super-
mix Universal (Invitrogen) using the ABI 7300 Re-
al-Time PCR system. The RT reactions were carried 
out at 25˚C for 5 minutes, 42˚C for 30 minutes, 85˚C for 
5 minutes and then held on 4˚C. The PCR reactions 
were performed under the following conditions, 50˚C 
for 2 minutes, 95˚C for 10 minutes and then 40 cycles 
of 95˚C for 15 seconds and 60˚C for 60 seconds. 18S 
rRNA gene was used for normalization. The qRT-PCR 
analyses for each miRNA and mRNA in three cell 
lines were performed in quadruplicates and triplicates 
respectively. Relative quantitation was calculated 
using the 2-Δ(ΔCt) method where fold change is equal to 
2-[(Mean ΔCt Target Gene) – (Mean ΔCt Internal Control)]. 
Transfection of miR-21 mimic and inhibitor in 
RB cell lines 
The miR-21 mimic is a small double-strand RNA 
that mimics endogenous precursor miRNA, and the 
miR-21 inhibitor is a single-strand RNA that is de-
signed to bind to and inhibit endogenous miRNA. 
Transfection of Weri-Rb1, Y79 and RB355 cell lines 
was executed with Lipofectamine™ 2000 (Invirtro-
gen) according to the manufacturer’s protocol. Briefly, 
cells were plated in 6-well plates at 30-50% confluence 
in antibiotics-free growth medium one day before 
transfection. To make the transfection complex, we 
diluted 70pmole of Pre-miR™ miRNA precursor, An-
ti- miR™ miRNA inhibitors (hsa-miR-21) or miRNA 
negative control (Ambion) with 5µl Lipofectamine™ 
2000 (Invirtrogen) in 2ml of Opti-MEM® I Reduced 
Medium (Invitrogen). Medium were changed to 
complete growth medium (20%FBS) after 4-6 hours. 
After 48 h transfection, total RNA and protein were 
isolated. 
Western blot assays 
Proteins were extracted from transfected cells 
using 10X RIPA lysis buffer (Millipore). Protein con-
centration was measured using the Pierce® BCA pro-
tein assay kit (Thermo). The primary anti-PDCD4 
(rabbit) antibody was purchased from Rockland 
(Gilbertsville, PA) and anti-β-actin (mouse) antibody 
was obtained from Sigma-Aldrich. Protein with 1X 
Laemmli buffer was denatured at 95˚C for 5 minutes 
before electrophoresis using the 10% 
Mini-PROTEAN® TGX Precast Gels (BIO-RAD), un-
der the condition of 120V, for 1 – 1.5 hours. Protein 
was transferred onto the nitrocellulose membrane. 
The membrane was blocked with 5% non-fat milk/ 
PBST for one hour at RT and incubated with the pri-
mary antibody (1:5,000 dilution) at 4 ˚C overnight. 
The secondary antibody (1:100,000 dilution) was ap-
plied for 1-1.5h at RT. The blot signals were detected 
using the SuperSignal West Dura Chemiluminescent 
Substrate (Thermo) and visualized via Image Lab™ 
system software (BIO-RAD). β-actin was used as an 
internal control. The band intensity was quantified 
using the Image J software. 
Statistical analysis 
Data were presented as the mean ± standard de-
viation (S.D.). The one-way analysis of variance 
(ANOVA) was performed for the miRNA differential 
expression in cell lines. The Student’s t-test was ap-
plied to compare two transfected groups. P-value ≤ 
.05 or .01 was considered statistically significant and 
presented with one and two asterisks respectively.  
 




Results and Discussion 
Differentially expressed miRNAs in three RB 
cell lines 
miRNAs, such as miR-19b, 93, -141 and 181c, 
miR-181a, -183, -222 and let-7a were identified earlier 
as RB-related miRNAs using a Human miRNA 2k 
custom array (Agilent) [24]. A separate study identi-
fied 11 over-expressed miRNAs in RB compared to 
normal retina, most notably a fourfold increase in 
miR-320, miR-373 and miR-503 using the miRCURYTM 
array microarray (Exiqon) [27]. To explore the relative 
expression of miRNAs in three RB cell lines, 
Weri-Rb1, Y79 and RB355, we selected a list of 23 
candidate miRNAs (miR-19b, -21, -26a, -29b, -93, -96, 
-141, -181a, -181c, -183, -187,-195, -200b, -200c, -205, 
-214, -222, -381,-556-3p, -557, -644, -1287 and let-7a) 
from aforementioned studies for qRT-PCR analysis. 
Interestingly, those miRNAs, such as miR-19, 
-21, -26, -29, -93, -96, -141, -181, -183, -195, -200b, -205 
and -222, were predicted to target one or more of the 
320 retinal genes, which are known to be involved in 
visual functions or related to inherited retinal diseases 
[52]. These target genes were identified by a combi-
nation of the RetinaCentral, the Retinal Information 
Network databases, and the comparison of retinal/ 
RPE dbEST libraries between five tissue-specific li-
braries [52]. 
In addition, we found that the expression of 
some miRNAs, such as miR-141, -187, -200b, 200c, -214 
and -381, was very low in all three RB cell lines (data 
not shown). Others, such as miR-195, miR-19b, 
miR-26a, miR-21 and miR-222 were extensively 
over-expressed in one cell line as compared to the 
other two (Figure 1). miR-19b was deregulated as 
previously reported [24] in RB cell lines, with greater 
expression in Weri-Rb1 than in Y79 cells and low lev-
els in RB355 cells. miR-26a, which is expressed in 
normal retina [52], appeared with significantly dif-
ferent expression levels among the three cell lines, 
with the highest expression being found in Y79 cells 
and a comparable expression level in both Wer-Rb1 
and RB355 cells. Others, such as miR-21 and miR-222, 
were well documented by independent studies in 
regards to their regulatory activity within a number of 
cancers and also showed differential expression in RB 
cells. It should be noted that four of the five miRNAs 
were commonly overexpressed in Y-79 cells as com-
pared to Rb-1 and Rb-355 cells. Alongside our previ-
ous observation of Y-79 cells as having increased po-
tency in metastasis and proliferation, we suggest 
those four miRNAs might have the ability to predict 
metastasis and proliferation of the RB. However, 
miR-19b was expressed higher exclusively in Rb-1 
cells and required further investigation.  
 
Figure 1. The differential expression patterns of miRNAs in three RB 
cells. Five miRNAs were identified by ANOVA tests to be overexpressed in 
one cell line compared to the other two. Four of the five miRNAs had a 
common increase in expression level in Y-79 cells, whereas miR-19b had a 
higher expression level in Weri-Rb1 cells (Rb1). All data were measured in 
triplicate and presented as the mean ± standard deviation (S.D.). 
 
Target gene prediction of the candidate 
miRNAs  
In order to understand how these five miRNAs 
function in RB tumor development and progression, 
predicted target genes of those five miRNAs were 
obtained via three computational algorithms, mi-
Randa (http://www.microrna.org/), TargetScan 
(http://www.targetscan.org/), and DianaMicroT 
(http://diana.cslab.ece.ntua.gr/microT/). For each 
miRNA, predicted target genes were displayed if at 
least predicted by two algorithms. The predicted 




Figure 2. Program prediction of target genes of miR-21. The 
Venn-diagram displays the putative targets genes of miR-21 as predicted by 
Diana MicroT, TargetScan, and Miranda. There were 202 candidates predicted 
by at least two programs and 46 candidates by all three algorithms.  
 




miR-21 and one of its target genes, PDCD4 in 
RB 
To study the biological significance of the dif-
ferentially expressed miRNAs, we predicted putative 
target genes, which were documented in previous 
studies. PDCD4 is one of the well reported targets of 
miR-21. Reduction or loss of PDCD4 expression was 
often seen in various cancers, including lung cancer 
[53], heptocellular carcinoma [54], ductal breast cancer 
[55], oral squamous cell carcinoma [56], and colorectal 
cancer [57]. PDCD4 protein levels were found to be 
inversely correlated with miR-21 levels in human 
glioblastoma cell lines [58], colorectal samples [41] 
and cell lines [59], and breast tumor specimens [35].  
Furthermore, the conserved target site for 
miR-21 in the 3’-UTR of PDCD4 was perfectly 
matched through bioinformatics predictions. The 
suppression of reporter gene activity with the 3’-UTR 
of PDCD4 verified the down-regulatory effect of 
miR-21 in colorectal cells [59], cervical carcinoma cells 
[60], glioblastoma cells [58], breast cancer cells [61], 
and myelogenous leukemia cells [62-64]. The Tar-
getScan program was applied to confirm the miR-21 
binding site in the 3’-UTR of PDCD4 and the sequence 
for the binding site was well conserved among species 
as shown in Figure 3. 
In glioblastoma T98G cells, high levels of miR-21 
repressed PDCD4 [58]. We reasoned that similar in-
teractions might also exist in RB. Thus, we assessed 
both PDCD4 mRNA and protein levels in RB cell 
lines, Rb1, Y79 and Rb355. We expected that PDCD4 
expression might be inversely correlated with miR-21 
expression. The implication being, cell lines with high 
endogenous miR-21 might contain a low level of 
PDCD4 protein, and vice versa. When compared be-
tween Rb1 and Y79 cells, miR-21 was barely detecta-
ble and the most abundant amount of PDCD4 protein 
was found in Rb1, whereas Y79 cells displayed a 
higher miR-21 level and low PDCD4 mRNA and 
protein (Figure 4.). Rb-355 cells have similarly low 
expression levels of miR-21 and high levels of PDCD4 
mRNA. However, Rb-355 rarely expressed the 
PDCD4 protein, indicating PDCD4 might be subject to 
more complex post-transcriptional regulation.  
Overexpression of PDCD4 could inhibit cell in-
vasion in MDA-MB-231 breast cancer cells [35] as well 
as OSCC cells [56]. We hypothesize that higher 
miR-21 levels accompanied by attenuated PDCD4 
protein levels in Y79 cell lines might be closely related 
to its more aggressive nature in tumor growth and 
metastasis. Meanwhile, lower miR-21 and 
up-regulated expression of PDCD4 protein in Rb1 
cells denotes its non-metastasis feature. As for RB355 
cells, knowledge is limited on the invasive ability and 





Figure 3. miR-21 seed sequence matches the target site in the 3’ 
UTR of PDCD4. The seed sequence of miR-21 was identified by TargetScan 




Figure 4. Expression of miR-21 and PDCD in RB cells. Total RNA and total protein were isolated from three RB cell lines by mirVana and RIPA respectively. 
qRT-PCR was performed to measure the expression level of miR-21 and PDCD4 mRNA. Western blot analysis was performed to measure the protein level of 
PDCD4. Y79 cells had the highest miR-21 level along with a low PDCD4 mRNA and protein level. Rb1 had a lower miR-21 expression level, but the highest PDCD4 








Previous studies also implied that the Y79 cell 
line represents more metastatic potential as compared 
to the Rb1 cell line. The metastatic characteristics of 
Y79 cells were observed after intravitreous cavity in-
jections in immune-deficient mice, while Rb1 cells 
represented a less-metastatic model [65]. Tumors 
formed in Y79-injected mice aggressively invaded 
subretinal and choroidal space, and then migrated to 
the optic nerve as well as the brain and contralateral 
optic nerve. On the other hand, the mice injected with 
Rb1 cells developed localized tumors located in the 
anterior uveal tissue. In vitro, suspended Y79 cells 
adhered to monkey choroid and rat C6 glioma cells, 
but not to human embryonic kidney cells. The binding 
of Y79 RB cells to the choroid and glioma cells, which 
were derived from target sites of invasion, were con-
firmed as true cell-cell interactions since trypsin 
treatment interrupted the binding of Y79 cells, but 
neuraminidase did not. Few Rb1 cells interacted with 
choroidal and glioma cells. It was believed that the 
distinct ability and inclination to metastasize in Rb1 
and Y79 RB cells might result from differences in 
membrane protein structure. Moreover, the invasive 
Y79 cells lost expression of N-cadherin and cadher-
in-11 proteins, contributing to RB tumor progression 
[66, 67]. Rb1 cells relied on cadherin-mediated cell-cell 
interaction [66], which is calcium-dependent [67]. Ec-
topic expression of N-cadherin and cadherin-11 in Y79 
cells transplanted into the vitreous of mice showed a 
less extensive optic nerve invasion, which was similar 
to Rb1 cell xenografts as compared to Y79 cell con-
trols.  
In a previous study, Dalgard et al. discovered 
that precursor and mature miR-34a in RB cell lines 
were expressed in different levels: they were higher in 
Rb1 cells and lower in Y79 cells [14]. In Y79 cells, the 
level of miR-34a rose after adding p53-activating 
agents. Overexpression of miR-34a diminished cell 
growth and increased caspase-3/7 activity in both RB 
cells, particularly in Y79 cells. It is likely that miR-34a 
expression levels represent the aggressiveness of both 
cells, due to the miRNAs’ epigenetic manipulation on 
RB cell lines contributing to invasion variability. Thus, 
Y79 seems to be more aggressive when compared to 
Weri-Rb1 cells, and higher expression level of miR-21 
along with diminished PDCD4 level might serve as an 
indicator of its aggressive nature. 
Inhibition or overexpression of miR-21 in RB 
cell lines 
We sought to explore whether or not miR-21 
regulates endogenous PDCD4 in RB cell lines Rb1 and 
Y79, as well as to observe the miR-21 and PDCD4 ex-
pression levels after transient transfections. The nega-
tive regulation of miR-21 on its target gene, PDCD4, 
has been established in other cancers. The protein 
expression level of PDCD4 could be down- and 
up-regulated by a miR-21 inhibitor and precursor 
respectively in OSCC cells [56] and cervical carcinoma 
Hela cells [60]. A similar study showed that an-
ti-miR-21 transfected in leukemia HL60 and K562 cells 
increased the mRNA and protein expression of 
PDCD4 [62-64].  
To validate the similar alterations of miR-21 and 
PDCD4, we performed qRT-PCR and Western blot-
ting to compare RB cells with miR-21 inhabitation and 
overexpression to negative controls. The transfection 
with the miR-21 inhibitor and mimic were efficient 
and could elevate miR-21 to more than 100-fold levels 
in cell lines when compared to negative controls in 
both Rb1 and Y79 cells (Figure 5).  
The PDCD4 protein level significantly decreased 
in Rb-1 and Y-79 cells when miR-21 is overexpressed. 
Meanwhile, inhibition of miR-21 successfully restored 
PDCD4 protein levels; eliminating the possibility that 
miR-21 overexpression silences PDCD4 due to the 
non-specific off-target binding effect.  
By targeting PDCD4, miR-21 could manage tu-
mor growth and invasion. In colorectal RKO cells that 
endogenously expressed high levels of miR-21, an-
ti-miR-21 transfection caused PDCD4 protein levels to 
increase and also blocked cell invasion and distal 
metastasis [59]. In a similar vein, pre-miR-21- 
transfected Colo206f cells that were naturally low in 
miR-21 displayed decreased PDCD4 protein levels 
and increased cell invasion. In cervical carcinoma 
Hela cells, the knockdown of miR-21 restrained cell 
proliferation and colony formation [60]. In parallel, 
elevated expression of miR-21 in RB via a precursor 
might consistently lessen PDCD4 expression, a re-
sponder to apoptosis in cancer, thus stimulating cell 
proliferation. In contrast, miR-21 inhibition might 
contribute to restoring PDCD4 expression in RB cells, 
resulting in suppression of tumor cell growth and 
invasion. These imply that miR-21 may serve as a 
therapeutic target by suppressing tumor growth and 
triggering apoptosis pathways by regulating PDCD4 
gene expression in RB.  
Conclusions 
Our data suggests that miR-21 may play a sig-
nificant regulatory role in RB tumor cell migration 
and invasion. Therefore, it may serve as a therapeutic 
target in RB as it regulates Rb1 gene expression by 
directly targeting PDCD4.  
 





Figure 5. Expression of PDCD4 mRNA and protein in Rb1 and Y79 cells when transfected by miR-21 mimic or inhibiotor. Rb1 and Y79 cells were 
transfected with miR-21 mimic and inhibitor respectively. Two days after transfection, total RNA and protein were isolated. qRT-PCR showed the inhibition and 
overexpression were successful in comparison with the wild type control. PDCD4 mRNA levels in Rb1 cells did not show a significant change, but a sigifnicant fold 
change was present in Y79 cell data. Western blotting revealed PDCD4 proteins in both cells as having an inverse correlation with the miR-21 level, in which miR-21 
overexpression reduced the PDCD4 protein while miR-21 inhibition restored the PDCD4 protein level. 
 
Acknowledgements 
We are grateful to Dr. Hakim Djaballah (Memo-
rial Sloan-Kettering Cancer Center, US) for providing 
the Weri-RB1, Y-79 and RB355 cell lines and Dr. Gail 
M. Seigel (State University of New York at Buffalo, 
US) for the gift of RB143, Y79 and WERI-RB27 cell 
lines. This research was supported in part by the 
Wendy Will Case award (to SWF), the Hao Founda-
tion Award (to SWF) and the Elaine H. Snyder Cancer 
Research Award (to SWF). 
Competing Interests 
The authors have declared that no competing 
interest exists. 
References 
1. Schefler AC, Abramson DH. Retinoblastoma: what is new in 2007-2008. Curr 
Opin Ophthalmol. 2008; 19: 526-34. doi:10.1097/ICU.0b013e328312975b 
00055735-200811000-00013 [pii]. 
2. Abramson DH. Retinoblastoma in the 20th century: past success and future 
challenges the Weisenfeld lecture. Invest Ophthalmol Vis Sci. 2005; 46: 
2683-91. doi:46/8/2684 [pii] 10.1167/iovs.04-1462. 
3. Melamud A, Palekar R, Singh A. Retinoblastoma. Am Fam Physician. 2006; 73: 
1039-44. 
4. Theodoropoulou S, Kolovou PE, Morizane Y, Kayama M, Nicolaou F, Miller 
JW, et al. Retinoblastoma cells are inhibited by aminoimidazole carboxamide 
ribonucleotide (AICAR) partially through activation of AMP-dependent ki-
nase. FASEB J. 2010;24: 2620-30. doi:fj.09-152546 [pii] 10.1096/fj.09-152546. 




5. Abramson DH, Ronner HJ, Ellsworth RM. Second tumors in nonirradiated 
bilateral retinoblastoma. Am J Ophthalmol. 1979; 87: 624-7. 
6. Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al. 
Mortality from second tumors among long-term survivors of retinoblastoma. J 
Natl Cancer Inst. 1993; 85: 1121-8. 
7. Bader JL, Miller RW, Meadows AT, Zimmerman LE, Champion LA, Voute PA. 
Trilateral retinoblastoma. Lancet. 1980; 2: 582-3. 
8. Draper GJ, Sanders BM, Brownbill PA, Hawkins MM. Patterns of risk of 
hereditary retinoblastoma and applications to genetic counselling. Br J Cancer. 
1992; 66: 211-9. 
9. Moll AC, Imhof SM, Bouter LM, Kuik DJ, Den Otter W, Bezemer PD, et al. 
Second primary tumors in patients with hereditary retinoblastoma: a regis-
ter-based follow-up study, 1945-1994. Int J Cancer. 1996; 67: 515-9. 
doi:10.1002/(SICI)1097-0215(19960807)67:4<515::AID-IJC9>3.0.CO;2-V. 
10. Shields CL, Shields JA, Baez K, Cater JR, De Potter P. Optic nerve invasion of 
retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994; 73: 
692-8. 
11. Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J, et al. 
Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Oph-
thalmol. 2002; 120: 923-31. doi:ecs10156 [pii]. 
12. Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma 
compared to normal retina. Mol Vis. 2010;16: 1292-303. 
13. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Pro-
ceedings of the National Academy of Sciences of the United States of America. 
1971; 68: 820-3. 
14. Dalgard CL, Gonzalez M, deNiro JE, O'Brien JM. Differential microRNA-34a 
expression and tumor suppressor function in retinoblastoma cells. Invest 
Ophthalmol Vis Sci. 2009; 50: 4542-51. doi:iovs.09-3520 [pii] 
10.1167/iovs.09-3520. 
15. Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, et al. Correlation of overex-
pression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, 
and proliferation associated with let-7 down-regulation in retinoblastomas. 
Hum Pathol. 2010;41: 493-502. doi:S0046-8177(09)00335-9 [pii] 
10.1016/j.humpath.2009.08.022. 
16. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor 
suppressors and oncogenes. Oncogene. 2006; 25: 6188-96. doi:1209913 [pii] 
10.1038/sj.onc.1209913. 
17. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identifi-
cation of hundreds of conserved and nonconserved human microRNAs. Nat 
Genet. 2005; 37: 766-70. doi:ng1590 [pii] 10.1038/ng1590. 
18. Sioud M, Cekaite L. Profiling of miRNA expression and prediction of target 
genes. Methods Mol Biol. 2010;629: 257-71. doi:10.1007/978-1-60761-657-3_16. 
19. Griffiths-Jones S, Grocock R, van Dongen S, Bateman A, Enright A. miRBase: 
microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 
2006; 34: D140 - D4. 
20. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for 
microRNA genomics. Nucleic Acids Res. 2008; 36: D154-8. doi:gkm952 [pii] 
10.1093/nar/gkm952. 
21. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA 
biogenesis, function and decay. Nat Rev Genet. 2010;11: 597-610. doi:nrg2843 
[pii] 10.1038/nrg2843. 
22. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev 
Mol Cell Biol. 2005; 6: 376-85. doi:nrm1644 [pii] 10.1038/nrm1644. 
23. Ambros V. The functions of animal microRNAs. Nature. 2004; 431: 350-5. 
doi:10.1038/nature02871 nature02871 [pii]. 
24. Huang JC, Babak T, Corson TW, Chua G, Khan S, Gallie BL, et al. Using 
expression profiling data to identify human microRNA targets. Nat Methods. 
2007; 4: 1045-9. doi:nmeth1130 [pii] 10.1038/nmeth1130. 
25. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a 
new paradigm for cancer gene therapy? Cancer Gene Ther. 2008; 15: 341-55. 
doi:cgt20088 [pii] 10.1038/cgt.2008.8. 
26. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. 
Human microRNA genes are frequently located at fragile sites and genomic 
regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101: 2999-3004. 
doi:10.1073/pnas.0307323101 0307323101 [pii]. 
27. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, et al. Identification of miRNAs 
associated with tumorigenesis of retinoblastoma by miRNA microarray anal-
ysis. Childs Nerv Syst. 2009; 25: 13-20. doi:10.1007/s00381-008-0701-x. 
28. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent 
deletions and down-regulation of micro- RNA genes miR15 and miR16 at 
13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99: 
15524-9. doi:10.1073/pnas.242606799242606799 [pii]. 
29. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. 
Reduced expression of the let-7 microRNAs in human lung cancers in associ-
ation with shortened postoperative survival. Cancer Res. 2004; 64: 3753-6. 
doi:10.1158/0008-5472.CAN-04-063764/11/3753 [pii]. 
30. Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ, Jr., et al. microRNA-21 
negatively regulates Cdc25A and cell cycle progression in colon cancer cells. 
Cancer research. 2009; 69: 8157-65. doi:0008-5472.CAN-09-1996 [pii] 
10.1158/0008-5472.CAN-09-1996. 
31. Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, et al. miR-638 mediated regu-
lation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in tri-
ple negative breast cancer. Breast cancer research : BCR. 2014; 16: 435. 
doi:10.1186/s13058-014-0435-5. 
32. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. Mi-
croRNA gene expression deregulation in human breast cancer. Cancer Res. 
2005; 65: 7065-70. doi:65/16/7065 [pii] 10.1158/0008-5472.CAN-05-1783. 
33. Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, et al. Role of deregulated 
microRNAs in breast cancer progression using FFPE tissue. PloS one. 2013; 8: 
e54213. doi:10.1371/journal.pone.0054213. 
34. Xu X, Jia R, Zhou Y, Song X, Wang J, Qian G, et al. Microarray-based analysis: 
identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J 
Oncol. 2011; 38: 1385-93. doi:10.3892/ijo.2011.961. 
35. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor 
suppressor genes in invasion and metastasis. Cell Res. 2008; 18: 350-9. 
doi:cr200824 [pii] 10.1038/cr.2008.24. 
36. Yan LX, Wu QN, Zhang Y, Li YY, Liao DZ, Hou JH, et al. Knockdown of 
miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migra-
tion and in vivo tumor growth. Breast Cancer Res. 13: R2. doi:bcr2803 [pii] 
10.1186/bcr2803. 
37. Song B, Wang C, Liu J, Wang X, Lv L, Wei L, et al. MicroRNA-21 regulates 
breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 
3 expression. J Exp Clin Cancer Res. 29: 29. doi:1756-9966-29-29 [pii] 
10.1186/1756-9966-29-29. 
38. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, et al. Downregulation of miR-21 
inhibits EGFR pathway and suppresses the growth of human glioblastoma 
cells independent of PTEN status. Lab Invest. 90: 144-55. doi:labinvest2009126 
[pii] 10.1038/labinvest.2009.126. 
39. Zhou X, Ren Y, Moore L, Mei M, You Y, Xu P, et al. Downregulation of miR-21 
inhibits EGFR pathway and suppresses the growth of human glioblastoma 
cells independent of PTEN status. Lab Invest. 2010; 90: 144-55. 
doi:labinvest2009126 [pii] 10.1038/labinvest.2009.126. 
40. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. 
MicroRNA 21 promotes glioma invasion by targeting matrix metalloprotein-
ase regulators. Mol Cell Biol. 2008; 28: 5369-80. doi:10.1128/MCB.00479-08 
MCB.00479-08 [pii]. 
41. Chang KH, Miller N, Kheirelseid EA, Ingoldsby H, Hennessy E, Curran CE, et 
al. MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg On-
col. 2011; 37: 597-603. doi:S0748-7983(11)00247-2 [pii] 
10.1016/j.ejso.2011.04.001. 
42. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and 
promotes apoptosis resistance and invasion in prostate cancer cells. Biochem 
Biophys Res Commun. 2009; 383: 280-5. doi:S0006-291X(09)00543-9 [pii] 
10.1016/j.bbrc.2009.03.077. 
43. Schramedei K, Morbt N, Pfeifer G, Lauter J, Rosolowski M, Tomm JM, et al. 
MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. On-
cogene. doi:onc201115 [pii] 10.1038/onc.2011.15. 
44. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. Mi-
croRNA-21 regulates expression of the PTEN tumor suppressor gene in hu-
man hepatocellular cancer. Gastroenterology. 2007; 133: 647-58. 
doi:S0016-5085(07)01002-5 [pii] 10.1053/j.gastro.2007.05.022. 
45. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) 
represses tumor suppressor PTEN and promotes growth and invasion in 
non-small cell lung cancer (NSCLC). Clin Chim Acta. 411: 846-52. 
doi:S0009-8981(10)00169-5 [pii] 10.1016/j.cca.2010.02.074. 
46. Jazdzewski K, Boguslawska J, Jendrzejewski J, Liyanarachchi S, Pachucki J, 
Wardyn KA, et al. Thyroid Hormone Receptor {beta} (THRB) Is a Major Target 
Gene for MicroRNAs Deregulated in Papillary Thyroid Carcinoma (PTC). J 
Clin Endocrinol Metab. 96: E546-53. doi:jc.2010-1594 [pii] 10.1210/jc.2010-1594. 
47. Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu W, et al. miR-21 plays a pivotal role 
in gastric cancer pathogenesis and progression. Lab Invest. 2008; 88: 1358-66. 
doi:labinvest200894 [pii] 10.1038/labinvest.2008.94. 
48. Ziyan W, Shuhua Y, Xiufang W, Xiaoyun L. MicroRNA-21 is involved in 
osteosarcoma cell invasion and migration. Med Oncol. 
doi:10.1007/s12032-010-9563-7. 
49. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, et al. 
MicroRNA expression distinguishes between germinal center B cell-like and 
activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer. 
2007; 121: 1156-61. doi:10.1002/ijc.22800. 
50. Liu M, Wu H, Liu T, Li Y, Wang F, Wan H, et al. Regulation of the cell cycle 
gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res. 2009; 19: 
828-37. doi:cr200972 [pii] 10.1038/cr.2009.72. 
51. Antczak C, Kloepping C, Radu C, Genski T, Muller-Kuhrt L, Siems K, et al. 
Revisiting old drugs as novel agents for retinoblastoma: in vitro and in vivo 
antitumor activity of cardenolides. Invest Ophthalmol Vis Sci. 2009; 50: 
3065-73. doi:iovs.08-3158 [pii] 10.1167/iovs.08-3158. 
52. Arora A, McKay GJ, Simpson DA. Prediction and verification of miRNA 
expression in human and rat retinas. Invest Ophthalmol Vis Sci. 2007; 48: 
3962-7. doi:48/9/3962 [pii] 10.1167/iovs.06-1221. 
53. Chen Y, Knosel T, Kristiansen G, Pietas A, Garber ME, Matsuhashi S, et al. 
Loss of PDCD4 expression in human lung cancer correlates with tumour pro-
gression and prognosis. J Pathol. 2003; 200: 640-6. doi:10.1002/path.1378. 
54. Zhang H, Ozaki I, Mizuta T, Hamajima H, Yasutake T, Eguchi Y, et al. In-
volvement of programmed cell death 4 in transforming growth fac-
tor-beta1-induced apoptosis in human hepatocellular carcinoma. Oncogene. 
2006; 25: 6101-12. doi:1209634 [pii] 10.1038/sj.onc.1209634. 
55. Wen YH, Shi X, Chiriboga L, Matsahashi S, Yee H, Afonja O. Alterations in the 
expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep. 2007; 18: 
1387-93. 




56. Reis PP, Tomenson M, Cervigne NK, Machado J, Jurisica I, Pintilie M, et al. 
Programmed cell death 4 loss increases tumor cell invasion and is regulated by 
miR-21 in oral squamous cell carcinoma. Mol Cancer. 2010; 9: 238. 
doi:1476-4598-9-238 [pii] 10.1186/1476-4598-9-238. 
57. Mudduluru G, Medved F, Grobholz R, Jost C, Gruber A, Leupold JH, et al. 
Loss of programmed cell death 4 expression marks adenoma-carcinoma tran-
sition, correlates inversely with phosphorylated protein kinase B, and is an 
independent prognostic factor in resected colorectal cancer. Cancer. 2007; 110: 
1697-707. doi:10.1002/cncr.22983. 
58. Chen Y, Liu W, Chao T, Zhang Y, Yan X, Gong Y, et al. MicroRNA-21 
down-regulates the expression of tumor suppressor PDCD4 in human glio-
blastoma cell T98G. Cancer Lett. 2008; 272: 197-205. doi:S0304-3835(08)00526-0 
[pii] 10.1016/j.canlet.2008.06.034. 
59. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et 
al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor sup-
pressor Pdcd4 and stimulates invasion, intravasation and metastasis in colo-
rectal cancer. Oncogene. 2008; 27: 2128-36. doi:1210856 [pii] 
10.1038/sj.onc.1210856. 
60. Yao Q, Xu H, Zhang QQ, Zhou H, Qu LH. MicroRNA-21 promotes cell pro-
liferation and down-regulates the expression of programmed cell death 4 
(PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun. 
2009; 388: 539-42. doi:S0006-291X(09)01592-7 [pii] 10.1016/j.bbrc.2009.08.044. 
61. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge 
CM. Estradiol downregulates miR-21 expression and increases miR-21 target 
gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 2009; 37: 
2584-95. doi:gkp117 [pii] 10.1093/nar/gkp117. 
62. Gu J, Zhu X, Li Y, Dong D, Yao J, Lin C, et al. miRNA-21 regulates arse-
nic-induced anti-leukemia activity in myelogenous cell lines. Med Oncol. 2011; 
28: 211-8. doi:10.1007/s12032-009-9413-7. 
63. Li Y, Zhu X, Gu J, Dong D, Yao J, Lin C, et al. Anti-miR-21 oligonucleotide 
sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Can-
cer Sci. 2010; 101: 948-54. doi:CAS1489 [pii] 10.1111/j.1349-7006.2010.01489.x. 
64. Li Y, Zhu X, Gu J, Hu H, Dong D, Yao J, et al. Anti-miR-21 oligonucleotide 
enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by 
inducing apoptosis. Hematology. 2010; 15: 215-21. 
doi:10.1179/102453310X12647083620840. 
65. Chevez-Barrios P, Hurwitz MY, Louie K, Marcus KT, Holcombe VN, Schafer 
P, et al. Metastatic and nonmetastatic models of retinoblastoma. Am J Pathol. 
2000; 157: 1405-12. doi:S0002-9440(10)64653-6 [pii] 
10.1016/S0002-9440(10)64653-6. 
66. Laurie N, Mohan A, McEvoy J, Reed D, Zhang J, Schweers B, et al. Changes in 
retinoblastoma cell adhesion associated with optic nerve invasion. Mol Cell 
Biol. 2009; 29: 6268-82. doi:MCB.00374-09 [pii] 10.1128/MCB.00374-09. 
67. Schiffman JS, Grunwald GB. Differential cell adhesion and expression of 
N-cadherin among retinoblastoma cell lines. Invest Ophthalmol Vis Sci. 1992; 
33: 1568-74. 
